Riociguat

利奥西呱

Report date: 2026/02/10 15:21:11
NMEFirst In Class

Base Information

Drug NameRiociguat
Drug Alias NameRiociguatum瑞司瓜特利奥昔夸Adempas安吉奥 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSoluble guanylate cyclase stimulants
TargetsSoluble guanylate cyclase
Therapy Area/IndicationsChronic thromboembolic pulmonary hypertensionUlcerScleroderma, Systemic +[13] 
Global Approved IndicationsChronic thromboembolic pulmonary hypertensionPulmonary Arterial HypertensionHypertension, Pulmonary
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2013/10/08
Country/TerritoryCzechiaBelgiumCanada +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesHumanis Saglık Anonim SirketiBeijing Anzhen Hospital, Capital Medical UniversityUniversity Of Colorado Denver +[10] 
Inactive CompaniesHeidelberg UniversityOttawa Heart Institute Research Corporation -Medical University Of Vienna
Active IndicationsChronic thromboembolic pulmonary hypertensionThrombosisVentricular Dysfunction, Left +[5] 
Inactive IndicationsUlcerScleroderma, SystemicRaynaud Disease +[8] 

Other Information

ATC CodeC02KX05
Related LinksWikipediaDrugBankKEGG